Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clinuvel Pharmaceuticals Limited (CLVLF)
OTHER OTC:CLVLF
RESEARCH TOOLSreports
Clinuvel Pharmaceuticals Limited (CLVLF) Stock Price & Analysis
27 Followers
CLVLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.42 - $14.20
Previous Close$10
Volume5.00
Average Volume (3M)2.14K
Market Cap
$513.59M
Enterprise Value$433.63M
Total Cash (Recent Filing)AU$121.51M
Total Debt (Recent Filing)AU$1.26M
Price to Earnings (P/E)24.7
Beta0.99
Next Earnings
Aug 28, 2024EPS Estimate
$0.26Last Dividend Ex-Date
Sep 05, 2023Dividend Yield0.34%
Share Statistics
EPS (TTM)0.41
Shares Outstanding50,103,765
10 Day Avg. Volume22
30 Day Avg. Volume2,142
Standard Deviation0.14
R-Squared0.12
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.51Price Target Upside65.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Clinuvel Pharmaceuticals Limited News
PremiumCompany Announcements
Clinuvel’s Afamelanotide Boosts DNA Repair After UV Exposure
PremiumCompany Announcements
CLINUvel CEO’s Tenure Extended for Smooth Transition
PremiumCompany Announcements
Clinuvel Pharmaceuticals Appoints Interim Secretary
PremiumCompany Announcements
Clinuvel’s SCENESSE® Gains Positive EMA Opinion
PremiumCompany Announcements
Clinuvel Explores New Parkinson’s TreatmentPremiumCompany Announcements
Clinuvel Advances in Photomedicine Market
PremiumCompany Announcements
Clinuvel Continues Share Buy-Back InitiativeOptions Prices
Currently, No data available
---
Ownership Overview
22.43% Insiders
2.80% Mutual Funds
2.56% Other Institutional Investors
72.22% Public Companies and
Individual Investors
CLVLF FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest stock price was $8.42 and its highest was $14.20 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Currently, no data Available
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Aug 28, 2024 which is in 54 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Feb 21, 2024. The company reported $0.141 earnings per share for the quarter, missing the consensus estimate of $0.171 by -$0.03.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of $0.03 which represents an annual dividend yield of 0.34%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is $0.26.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,103,764 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of $0.141 in its last earnings report, missing expectations of $0.171. Following the earnings report the stock price went down -6.635%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in CLVLF
---
Clinuvel Pharmaceuticals Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.51 (65.10% Upside)
$16.51 (65.10% Upside)
Blogger Sentiment
Bullish
CLVLF Sentiment 95%
Sector Average 71%
Sector Average 71%
Fundamentals
Return on Equity
18.60%
Trailing 12-Months
Asset Growth
32.88%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Ltd. is a global biopharmaceutical company. It engages in the the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
---
CLVLF Earnings Call
Q2 2024
0:00 / 0:00
---
CLVLF Stock 12 Month Forecast
Average Price Target
$16.51
▲(65.10% Upside)
Technical Analysis
Best Analysts Covering CLVLF
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-7.37%
reiterated a buy rating 10 days ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -7.37% per trade.
---